MoonLake Immunotherapeutics (MLTX): Long-Term Debt
$74.10M
As of 2025-12-31
$99.51M
As of 2026-06-30
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $74.10M | n/a | 2026-02-25, Balance as of period end |
| 2024-12-31 | $0 | n/a | 2026-02-25, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $74.10M | n/a |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $108.96M | +1.6% |
| Harrow, Inc. (HROW) | 2025-12-31 | $250.00M | -4.8% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $220.34M | -5.1% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $48.25M | +24.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $202.83M | +34.5% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $52.50M | -12.5% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $96.37M | n/a |
| Omeros Corp (OMER) | 2025-12-31 | $87.90M | -46.7% |
Compare MLTX, ARQT, HROW, XERS side by side · Screen every company in Pharmaceutical Preparations ↗